CompletedPhase 1

Study of Bemnifosbuvir on Cardiac Repolarization in Healthy Subjects

Canada35 participantsStarted 2023-04-25

Plain-language summary

This study will assess the effects of Bemnifosbuvir on cardiac repolarization in healthy Adult Subjects

Who can participate

Age range18 Years – 55 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Must agree to use two methods of birth control from Screening through 90 days after administration of the last dose of study drug * Females must have a negative pregnancy test at Screening and prior to dosing * Minimum body weight of 50 kg and body mass index (BMI) of 18-29 kg/m2 * Willing to comply with the study requirements and to provide written informed consent Exclusion Criteria: * Pregnant or breastfeeding * Infected with hepatitis B virus, hepatitis C virus, HIV or COVID-19 * Abuse of alcohol or drugs * Use of other investigational drugs within 28 days of dosing * Other clinically significant medical conditions or laboratory abnormalities

What they're measuring

Placebo-corrected (Δ) change-from-baseline QTc (ΔΔQTc).

Timeframe: 24 hours prior to dosing thru 48 hours post dose

Trial details

NCT IDNCT05905484

SponsorAtea Pharmaceuticals, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2023-05-31

View on ClinicalTrials.gov More Healthy Volunteer Study trials